Corneal Epithelium Defect Clinical Trial
Official title:
Efficacy, Tolerability and Comfort of GenTeal and GenTeal Gel, (0.3% Hypromellose) in the Pre- and Post- Operative Treatment of Patients Undergoing LASIK Surgery
Verified date | February 2016 |
Source | Georgia Regents University |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
GenTeal gel is an artificial tear gel used to lubricate the surface of the eye. This study will evaluate the effect of GenTeal gel on comfort following LASIK surgery. Participants will be asked to come to the clinic for three regularly scheduled visits after LASIK surgery: Day 1 (one day after LASIK surgery), Day 7 (one week follow-up), and Day 30 (one month follow-up). Participants will be asked to complete a questionnaire regarding eye comfort during each follow up visit. Participants will be randomly assigned to one of two groups, one of which will receive Genteal Gel four times a day for five days prior to surgery. The other group will receive no preoperative gel or lubricant, which has been our standard approach for many years.
Status | Completed |
Enrollment | 80 |
Est. completion date | October 2009 |
Est. primary completion date | October 2009 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 60 Years |
Eligibility |
Inclusion Criteria: 1. Age 18 - 60 2. Both sexes 3. Any race 4. Seeking LASIK surgery at the Medical College of Georgia (MCG)/Eye Care One 5. Meeting all established criteria for appropriateness for LASIK established by MCG/Eye Care One Exclusion Criteria: 1. Any corneal pathology including scars, prior herpes keratitis, prior corneal transplant 2. Any immunocompromised state including diabetes mellitus, cancer, HIV infection, or Hepatitis B or C. 3. Failure to meet all established criteria for appropriateness for LASIK established by MCG/Eye Care One |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | EyeCare One | Augusta | Georgia |
Lead Sponsor | Collaborator |
---|---|
Georgia Regents University | Novartis |
United States,
Samuel MA, Kaufman SC, Ahee JA, Wee C, Bogorad D. Diffuse lamellar keratitis associated with carboxymethylcellulose sodium 1% after laser in situ keratomileusis. J Cataract Refract Surg. 2002 Aug;28(8):1409-11. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Epithelial Healing After Laser Assisted in Situ Keratomileusis (LASIK) Surgery | Assess whether preoperative GenTeal Gel enhances epithelial healing after LASIK surgery within the first post-operative week, compared to control (no preoperative lubricant). Healing of the area of the cornea covering the radius of the sectioned into clock hours 0 - 12 where 0 hours equals no healing and 12 hours equals complete healing. | Day 1, End of Week 1 | No |
Secondary | Post Operative Pain Level | Assess whether preoperative GenTeal Gel alleviates post operative pain in LASIK surgery patients compared to control (no preoperative lubricant) as measured by patient completion of the Universal Pain Assessment Tool (moderate), a ten point scale with 0 being no pain and 10 being the worst pain possible. Data on the level of pain only in the right eye will be collected. | Day 1, End of Week 1 | No |
Secondary | Tolerability and Alleviation of Post-operative Pain in LASIK Surgery | A comparison of subjective comfort level defined as tolerability and alleviation of post-operative pain experienced as a result of post-operative application of GenTeal drops. Subjective pain level was measured on a 10 point likert scale where 0 = no pain and 10 = worst pain possible. A lower score at Week 1 as compared to Day 1 was considered improved. A same score or higher at week 1 as compared to day 1 was considered no improvement. | Week 1 post surgery | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04820010 -
Topical Insulin - Utility and Results in Neurotrophic Keratopathy in Stages 2 and 3
|
||
Recruiting |
NCT05204329 -
Safety of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease
|
Early Phase 1 | |
Completed |
NCT06209203 -
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of ZKY001 Eye Drops
|
Phase 2 |